Please login to the form below

Not currently logged in
Email:
Password:

Actavis claims top UK generics spot with Auden Mckenzie buy

Firm claims the deal will make it the UK’s third-largest pharma manufacturer
Actavis headquarters

Ireland-based Actavis has agreed to buy privately owned Auden Mckenzie for £306m ($461m) in a deal that will make it the biggest generics company in the UK.

The latest deal adds around 175 generic and specialty pharmaceutical products to Actavis' 650-strong portfolio - along with another 40 in the pipeline - and bolsters the Irish firm's position in sterile injectables such as Synastone (methadone) for treating heroin addiction.

Actavis is no stranger to growth by acquisition and the new deal comes after a busy 2014 which saw the company sign a string of takeover deals - headed by a $66bn merger with US specialty drugmaker Allergan that was forged despite competition from Valeant and has yet to close.

Other acquisitions in the last 12 months have included $25bn for Forest Laboratories, $2.9bn for Aptalis, a $1.6bn deal for Furiex Pharma and $675m for Durata. All told, the tally of M&A spending under chief executive Brent Saunders - who took over at Actavis last May - is now almost $100bn.

The Irish firm claims that when the Allergan and Auden Mckenzie deals close it will become the third-largest pharmaceutical manufacturer in the UK.

As a privately held company Auden Mckenzie's financial figures are not disclosed, but Actavis described the business as "profitable and growing" and in 2012/13 the company earned a reported £29m on sales of around £52m.

The latest acquisition will be made with cash and - subject to approval by regulatory authorities - is expected to close before the end of the first quarter. Shareholders in Auden Mckenzie will also get a two-year royalty on a percentage of gross profits for one of the company's products.

"This strategic combination is highly synergistic with our UK business, is immediately and highly accretive and reflects our commitment to invest to achieve a top position in key international markets," commented Robert Stewart, Actavis' chief operating officer.

Amit Patel, managing director of Auden Mckenize, said the two companies shared a "dynamic and entrepreneurial approach to developing and marketing generic medicines."

Article by
Phil Taylor

27th January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics